68
Participants
Start Date
November 7, 2022
Primary Completion Date
June 13, 2024
Study Completion Date
June 13, 2024
ZP8396
"Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used."
Drug: Placebo (ZP8396)
"Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin)."
Profil Institut für Stoffwechselforschung GmbH, Neuss
Lead Sponsor
Zealand Pharma
INDUSTRY